Thrombotic risk markers: tissue plasminogen activator/tissue plasminogen activator inhibitor-1 complex (Part 1)
https://doi.org/10.24884/2078-5658-2025-22-6-97-106
Abstract
The fibrinolysis system is one of the most important regulators of homeostasis and participates in maintaining stable blood flow. The key element of this system is the balance of plasminogen activators and inhibitors, which can be considered as markers of normal physiological and pathological reactions. The use of laboratory determination of the level of the tissue plasminogen activator/tissue plasminogen activator inhibitor-1 (t-PA/PAI-1) complex in clinical practice is promising in diagnostic and prognostic terms as a biomarker of increased thrombotic risk in the early stages of the development of complications of the disease. This review will provide up-to-date information on the structure, functions, diagnostic capabilities, and use in medical practice of such a marker of thrombotic risk as the t-PA/PAI-1 complex in VTE, sepsis, DIC and oncology.
About the Authors
M. M. Tanashyan
Russian Center of Neurology and Neurosciences
Russian Federation
Russian Federation
Tanashyan Marine M., Dr. of Sci. (Med.), Professor, Academician of RAS, Deputy Director for Science, Head of the 1st Neurological Department, Institute of Clinical and Preventive Neurology
Scopus Author ID: 6506228066, WoS ResearcherID: F-8483-2014
80, Volokolamskoe Shosse, Moscow, 125367
E. V. Roitman
Russian Center of Neurology and Neurosciences ; Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
Roitman Eugene V., Dr. of Sci. (Biol.), Leading Research Fellow; Professor, Department of Oncology, Hematology and Radiation Therapy
Scopus Author ID: 7004167632, WoS ResearcherID: M-6541-2017
80, Volokolamskoe Shosse, Moscow, 125367
1, Ostrovityanova str., Moscow, 117513
A. A. Raskurazhev
Russian Center of Neurology and Neurosciences
Russian Federation
Russian Federation
Raskurazhev Anton A., Cand. of Sci. (Med.), Neurologist, Senior Research Fellow, 1st Neurological Department, Institute of Clinical and Preventive Neurology
80, Volokolamskoe Shosse, Moscow, 125367
P. I. Kuznetsova
Russian Center of Neurology and Neurosciences
Russian Federation
Russian Federation
Kuznetsova Polina I., Cand. of Sci. (Med.), Research Fellow, 1st Neurological Department, Institute of Clinical and Preventive Neurology
80, Volokolamskoe Shosse, Moscow, 125367
A. S. Mazur
Russian Center of Neurology and Neurosciences
Russian Federation
Russian Federation
Mazur Andrey S., Postgraduate Student, 1st Neurological Department, Institute of Clinical and Preventive Neurology
80, Volokolamskoe Shosse, Moscow, 125367
References
1. Zhalyalov A. S. Study of spatial dynamics of fibrin clot growth and lysis in thrombolytic therapy: Avtoref. dis… kand. med. nauk. Moscow, 2019. 24 p. (In Russ.).
2. Zhalyalov A. S., Balandina A. N., Kuprash A. D. et al. The overview of fibrinolysis system contemporary concepts and of its disorders diagnostic methods. Voprosy gematologii/onkologii i immunopatologii v pediatrii. 2017;16(1):69–82. (In Russ.). http://doi.org/10.24287/1726-1708-2017-16-1-69-82.
3. Momot A. P., Lebedeva E. I., Nikolaeva M. G. et al. Clinical effects of intermittent pneumatic compression. Problemy reprodukcii. 2019;25(4):35–42. (In Russ.). http://doi.org/10.17116/repro20192504135.
4. Ryabinkina Yu. V., Piradov M. A., Tanashyan M. M. et al. Venous thrombogenesis and functional state of the hemorheology and hemostasis system in stroke patients. Annaly klinicheskoj i eksperimental’noj nevrologii. 2016;10(1):6–13. (In Russ.). http://doi.org/10.17816/psaic76.
5. Tanashyan M. M., Raskurazhev A. A., Shabalina A. A. et al. Biomarkers of cerebral atherosclerosis: the capabilities of early diagnosis and prognosis of individual risk. Annaly klinicheskoj i eksperimental’noj nevrologii. 2015;9(3):20–25. (In Russ.).
6. Tanashyan M. M., Shabalina A. A., Roitman E. V. et al. Thrombogenicity in patients with ischemic stroke and pre-existing polycythemia vera. Vestnik Rossijskogo gosudarstvennogo medicinskogo universiteta. 2020;(4):49–55. (In Russ.). http://doi.org/10.24075/vrgmu.2020.052.
7. Asakura H., Jokaji H., Saito M. et al. Changes in plasma levels of tissue-plasminogen activator/inhibitor complex and active plasminogen activator inhibitor in patients with disseminated intravascular coagulation. Am J Hematol. 1991;36(3):176–183. http://doi.org/10.1002/ajh.2830360304.
8. Bai H., Shen L., Zhang H., Tang N. Clinical value of TAT, PIC and t-PAIC as predictive markers for severe sepsis in pediatric patients. Front Pediatr. 2024;12:1336583. http://doi.org/10.3389/fped.2024.1336583.
9. Bollen L., Peetermans M., Peeters M. et al. Active PAI-1 as marker for venous thromboembolism: case-control study using a comprehensive panel of PAI-1 and TAFI assays. Thromb Res. 2014;134(5):1097–1102. http://doi.org/10.1016/j.thromres.2014.08.007.
10. Bourrienne M.-C., Loyau S., Faille D. et al. Impaired fibrinolysis in JAK2V617F-related myeloproliferative neoplasms. J Thromb Haemost. 2024;22(11):3199–3208. http://doi.org/10.1016/j.jtha.2024.07.031.
11. Chan O. T. M., Furuya H., Pagano I. et al. Association of MMP-2, RB and PAI-1 with decreased recurrence-free survival and overall survival in bladder cancer patients. Oncotarget. 2017;8(59):99707–99721. http://doi.org/10.18632/oncotarget.20686.
12. Chen R., Petrazzini B. O., Malick W. A. et al. Prediction of venous thromboembolism in diverse populations using machine learning and structured electronic health records. Arterioscler Thromb Vasc Biol. 2024;44(2):491–504. http://doi.org/10.1161/ATVBAHA.123.320331.
13. Chen Q., Shou W., Wu W. et al. Performance evaluation of thrombomodulin, thrombin-antithrombin complex, plasmin-α2-antiplasmin complex, and t-PA: PAI-1 complex. J Clin Lab Anal. 2019;33(6):e22913. http://doi.org/10.1002/jcla.22913.
14. Frischmuth T., Hindberg K., Aukrust P. et al. Elevated plasma levels of plasminogen activator inhibitor-1 are associated with risk of future incident venous thromboembolism. J Thromb Haemost. 2022;20(7):1618–1626. http://doi.org/10.1111/jth.15701.
15. Fu Y., Liu Y., Jin Y., Jiang H. Value of coagulation and fibrinolysis biomarker in lung cancer patients with thromboembolism. Zhongguo Fei Ai Za Zhi. 2018;21(8):583–587. (In Chinese). http://doi.org/10.3779/j.issn.1009-3419.2018.08.03.
16. Gehlot P., Brünnert D., Kaushik V. et al. Unconventional localization of PAI-1 in PML bodies: A possible link with cellular growth of endothelial cells. Biochem Biophys Rep. 2024;39:101793. http://doi.org/10.1016/j.bbrep.2024.101793.
17. Guo Q. Y., Peng J., Shan T.C., Xu M. Risk factors for mortality in critically ill patients with coagulation abnormalities: a retrospective cohort study. Curr Med Sci. 2024;44(5):912–922. http://doi.org/10.1007/s11596-024-2920-0.
18. Hayashi M., Ohmori S., Kawai Y., Moriguchi T. Endothelial GATA3 is involved in coagulofibrinolytic homeostasis during endotoxin sepsis. Exp Anim. 2025;74(1):104–113. http://doi.org/10.1538/expanim.24-0079.
19. Hong L. R., Chen Y. J., Jiang Q. L. et al. Predictive value of four items of new thrombus markers combined with conventional coagulation tests for thrombosis in antiphospholipid syndrome.Beijing Da Xue Xue Bao Yi Xue Ban. 2023;55(6):1033–1038. (In Chinese). http://doi.org/10.19723/j.issn.1671-167X.2023.06.012.
20. Hoshino K., Kitamura T., Nakamura Y. et al. Usefulness of plasminogen activator inhibitor-1 as a predictive marker of mortality in sepsis. J Intensive Care. 2017;5(1):42. http://doi.org/10.1186/s40560-017-0238-8.
21. Hoshino K., Nakashio M., Maruyama J. et al. Validating plasminogen activator inhibitor-1 as a poor prognostic factor in sepsis. Acute Med Surg. 2020;7(1):e581. http://doi.org/10.1002/ams2.581.
22. Huang K., Mo Q., Liao C. et al. The clinical significance of TAT, PIC, TM, and t-PAIC in vascular events of BCR/ABL-negative myeloproliferative neoplasms. Clin Exp Med. 2024;24(1):107. http://doi.org/10.1007/s10238-024-01371-7.
23. Huang L., Deng X., Fan R.-Z. et al. Coagulation and fibrinolytic markers offer utility when distinguishing between benign and malignant gallbladder tumors: A cross-sectional study. Clin Chim Acta. 2024;560:119751. http://doi.org/10.1016/j.cca.2024.119751.
24. Jee J., Brannon A. R., Singh R. et al. DNA liquid biopsy-based prediction of cancer-associated venous thromboembolism. Nat Med. 2024;30(9):2499–2507. http://doi.org/10.1038/s41591-024-03195-0.
25. Jevrić M., Matić I. Z., Krivokuća A. et al. Association of uPA and PAI-1 tumor levels and 4G/5G variants of PAI-1 gene with disease outcome in luminal HER2-negative node-negative breast cancer patients treated with adjuvant endocrine therapy. BMC Cancer. 2019;19(1):71. http://doi.org/10.1186/s12885-018-5255-z.
26. Ji Y., Qin Y., Tan Q. et al. Development of a chemiluminescence assay for tissue plasminogen activator inhibitor complex and its applicability to gastric cancer. BMC Biotechnol. 2024;24(1):30. http://doi.org/10.1186/s12896-024-00850-9.
27. Johansson L., Jansson J. H., Boman K. et al. Tissue plasminogen activator, plasminogen activator inhibitor-1, and tissue plasminogen activator/plasminogen activator inhibitor-1 complex as risk factors for the development of a first stroke. Stroke. 2000;31(1):26–32. http://doi.org/10.1161/01.str.31.1.26.
28. Li H., Shinohara E. T., Cai Q. Plasminogen activator inhibitor-1 promoter polymorphism is not associated with the aggressiveness of disease in prostate cancer. Clin Oncol (R Coll Radiol). 2006;18(4):333–337. http://doi.org/10.1016/j.clon.2006.02.005.
29. Li Y., Li H., Wang Y. et al. Potential Biomarkers for Early Diagnosis, Evaluation, and Prognosis of Sepsis-Induced Coagulopathy. Clin Appl Thromb Hemost. 2023;29:10760296231195089. http://doi.org/10.1177/10760296231195089.
30. Ling L., Huang X., Liu C. et al. Monitoring coagulation-fibrinolysis activation prompted timely diagnosis of hemophagocytic lymphohistiocytosis-related disseminated intravascular coagulation. Thrombosis J. 2021;19(1):82. http://doi.org/10.1186/s12959-021-00338-y.
31. López-Núñez J. J., Trujillo-Santos J., Monreal M. Management of venous thromboembolism in patients with cancer. J Thromb Haemost. 2018;16(12):2391–2396. http://doi.org/10.1111/jth.14305.
32. Mathews S. G., Krishna R. B. D., Lavanya M. et al. The role of the plasminogen activator inhibitor 1 (pai1) in ovarian cancer: mechanisms and therapeutic implications. Glob Med Genet. 2024;11(4):358–365. http://doi.org/10.1055/s-0044-1791734.
33. Mei H., Jiang Y., Luo L. et al. Evaluation the combined diagnostic value of TAT, PIC, tPAIC, and sTM in disseminated intravascular coagulation: A multi-center prospective observational study. Thromb Res. 2019;173:20–26. http://doi.org/10.1016/j.thromres.2018.11.010.
34. Nakatsuka E., Sawada K., Nakamura K. et al. Plasminogen activator inhibitor-1 is an independent prognostic factor of ovarian cancer and IMD-4482, a novel plasminogen activator inhibitor-1 inhibitor, inhibits ovarian cancer peritoneal dissemination. Oncotarget. 2017;8(52):89887–89902. http://doi.org/10.18632/oncotarget.20834.
35. Nicolaides A. N., Fareed J., Spyropoulos A. C. et al. Prevention and management of venous thromboembolism. International Consensus Statement. Guidelines according to scientific evidence. Int Angiol. 2024;43(1):1–222. http://doi.org/10.23736/S0392-9590.23.05177-5.
36. Nordenhem A., Wiman B. Tissue plasminogen activator (tPA) antigen in plasma: correlation with different tPA/inhibitor complexes. Scand J Clin Lab Invest. 1998;58(6):475–483. http://doi.org/10.1080/00365519850186274.
37. Nosaka M., Ishida Y., Kuninaka Y. et al. Immunohistochemical detection of uPA, tPA, and PAI-1 in a stasis-induced deep vein thrombosis model and its application to thrombus age estimation. Int J Legal Med. 2012;126:421–425. http://doi.org/10.1007/s00414-012-0680-z.
38. Qiu Y., Han S., Ji Y. Development of a thrombin-antithrombin complex detection kit and study in venous thromboembolism complicated by cervical cancer. BMC Biotechnol. 2024;24(1):103. http://doi.org/10.1186/s12896-024-00930-w.
39. Ren W., Zhang J., Chen Y. Evaluation of Coagulation, Fibrinolysis and Endothelial Biomarkers in Cirrhotic Patients With or Without Portal Venous Thrombosis. Clin Appl Thromb Hemost. 2020;26:1076029620982666. http://doi.org/10.1177/1076029620982666.
40. Sotiropoulos G. P., Kotopouli M., Karampela I. et al. Circulating plasminogen activator inhibitor-1 activity: a biomarker for resectable non-small cell lung cancer? J BUON. 2019;24(3):943–954.
41. Sternlicht M. D., Dunning A. M., Moore D. H. et al. Prognostic value of PAI1 in invasive breast cancer: evidence that tumor-specific factors are more important than genetic variation in regulating PAI1 expression. Cancer Epidemiol Biomarkers Prev. 2006;15(11):2107–2114. http://doi.org/10.1158/1055-9965.EPI-06-0351.
42. Swarbreck S. B., Secor D., Ellis C. G. et al. Effect of ascorbate on plasminogen activator inhibitor-1 expression and release from platelets and endothelial cells in an in-vitro model of sepsis. Blood Coagul Fibrinolysis. 2015;26(4):436–442. http://doi.org/10.1097/MBC.0000000000000273.
43. Tjärnlund-Wolf A., Brogren H., Lo E. H., Wang X. Plasminogen activator inhibitor-1 and thrombotic cerebrovascular diseases. Stroke. 2012; 43(10):2833–2839. http://doi.org/10.1161/STROKEAHA.111.622217.
44. Urano T., Castellino F.J., Suzuki Y. Regulation of plasminogen activation on cell surfaces and fibrin. J Thromb Haemost. 2018;16(8):1487–1497. http://doi.org/10.1111/jth.14157.
45. Watanabe R., Wada H., Miura Y. et al. Plasma levels of total plasminogen activator inhibitor-I (PAI-I) and tPA/PAI-1 complex in patients with disseminated intravascular coagulation and thrombotic thrombocytopenic purpura. Clin Appl Thromb Hemost. 2001;7(3):229–233. http://doi.org/10.1177/107602960100700309.
46. de Witte J. H., Sweep C. G., Klijn J. G. et al. Prognostic value of tissue-type plasminogen activator (tPA) and its complex with the type-1 inhibitor (PAI-1) in breast cancer. Br J Cancer. 1999;80(1–2):286–294. http://doi.org/10.1038/sj.bjc.6690353.
47. Wrzeszcz K., Słomka A., Zarychta E. et al. Tissue Plasminogen Activator as a Possible Indicator of Breast Cancer Relapse: A Preliminary, Prospective Study. J Clin Med. 2022;11(9):2398. http://doi.org/10.3390/jcm11092398.
48. Wu Z., Du Y., Cai X., Xu Q. Caprini score combined with thrombotic molecular markers for predicting DVT in patients with traumatic fractures. Sci Rep. 2025;15(1):1847. http://doi.org/10.1038/s41598-025-85941-z.
49. Yang Y., Feng G., Yan J. et al. Plasminogen activator inhibitor-1, thrombin-antithrombin, and prothrombin fragment F1+2 have higher diagnostic values than D-dimer for venous thromboembolism after TKA. Clin Appl Thromb Hemost. 2022;28:10760296221097383. http://doi.org/10.1177/10760296221097383.
50. Zhang J., Xue M., Chen Y. et al. Identification of soluble thrombomodulin and tissue plasminogen activator-inhibitor complex as biomarkers for prognosis and early evaluation of septic shock and sepsis-induced disseminated intravascular coagulation. Ann Palliat Med. 2021;10(10):10170–10184. http://doi.org/10.21037/apm-21-2222.
51. Zhang Q., Jin Y., Li X. et al. Plasminogen activator inhibitor-1 (PAI-1) 4G/5G promoter polymorphisms and risk of venous thromboembolism – a meta-analysis and systematic review. Vasa. 2020;49(2):141–146. http://doi.org/10.1024/0301-1526/a000839.
52. Zhong L., Dou J., Lin Q. et al. Tissue-Type Plasminogen Activator-Inhibitor Complex as an Early Predictor of Septic Shock: A Retrospective, Single-Center Study. Dis Markers. 2022;2022:9364037. http://doi.org/10.1155/2022/9364037.
53. Zhou Y., He L.-P., Qi Y.-H. et al. Diagnostic value of tissue plasminogen activator-inhibitor complex in sepsis-induced liver injury: A single-center retrospective case-control study. World J Hepatol. 2024;16(11):1255–1264. http://doi.org/10.4254/wjh.v16.i11.1255.
54. Zubac D. P., Wentzel-Larsen T., Seidal T., Bostad L. Type 1 plasminogen activator inhibitor (PAI-1) in clear cell renal cell carcinoma (CCRCC) and its impact on angiogenesis, progression and patient survival after radical nephrectomy. BMC Urol. 2010;10:20. http://doi.org/10.1186/1471-2490-10-20.
Review
For citations:
Tanashyan M.M., Roitman E.V., Raskurazhev A.A., Kuznetsova P.I., Mazur A.S. Thrombotic risk markers: tissue plasminogen activator/tissue plasminogen activator inhibitor-1 complex (Part 1). Messenger of ANESTHESIOLOGY AND RESUSCITATION. 2025;22(6):97-106. (In Russ.) https://doi.org/10.24884/2078-5658-2025-22-6-97-106
Email this article 